|
Mareev et al, 2021 [23]
|
RCT |
43 |
COVID-19 |
61.9 (10.6) |
59.9 (18.8) |
30 (69.8) |
13 (3.2) |
1 mg during the first 1–3 days followed by 0.5 mg/day |
|
Holby et al, 2021 [22]
|
RCT |
11340 |
COVID-19 within 24h |
63.3 (13.8) |
63.5 (13.7) |
5609 (49.4) |
28 |
N/A |
|
Tardif et al, 2021 [20]
|
RCT |
4488 |
COVID-19 within 24 h of enrolment |
53·7 (10.4) |
54·0 (10.4) |
2067 (46.1) |
30 |
0·5 mg orally administered twice per day for the first 3 days and then once per day for 27 days |
|
Deftereos et al, 2020 [21]
|
RCT |
105 |
Hospitalized with COVID-19 |
59.7 (4.6) |
62.7 (11.4) |
61 (58.1) |
21 |
1.5-mg loading dose followed by 0.5 mg after 60 min and maintenance doses of 0.5 mg twice daily) with standard medical treatment for as long as 3 weeks |
|
Lopes et al, 2021 [19]
|
RCT |
72 |
Moderate-severe COVID-19 |
53.8 (17.0) |
54.7 (19.3) |
35 (48.6) |
7.0 (3.0) |
0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days; if bodyweight ≥80 kg, the first dose was 1.0 mg |
